Bellevue Asset Management, LLC Cytokinetics Inc Transaction History
Bellevue Asset Management, LLC
- $208 Million
- Q3 2025
A detailed history of Bellevue Asset Management, LLC transactions in Cytokinetics Inc stock. As of the latest transaction made, Bellevue Asset Management, LLC holds 19 shares of CYTK stock, worth $1,262. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19Holding current value
$1,262% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding CYTK
# of Institutions
446Shares Held
135MCall Options Held
5.25MPut Options Held
1.18M-
T. Rowe Price Investment Management, Inc. Baltimore, MD19.1MShares$1.27 Billion0.64% of portfolio
-
Black Rock Inc. New York, NY14.7MShares$975 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.9MShares$788 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA7.41MShares$492 Million0.07% of portfolio
-
Paul Tudor Jones Tudor Investment Corp Et Al | Stamford, Ct6MShares$399 Million0.17% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $6.25B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...